Juntao Ran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juntao Ran has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Tanglong Zhang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
3 shared publicationsZhuoya Zhang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
3 shared publicationsHongxin Su
The First Hospital of Lanzhou University, Lanzhou, China
2 shared publicationsHuanyu Zhang
The First Hospital of Lanzhou University, Lanzhou, China
2 shared publicationsJian Gan
The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, PR China
2 shared publicationsJiangtao Wang
The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, PR China
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17  (1)
Core clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy
Boron Neutron Capture Therapy (BNCT) is a binary targeted radiotherapy modality based on nuclear capture reactions. This technique exploits the tumor-targeting capability of boron compounds and their high thermal neutron capture cross-section, inducing localized nuclear reactions within cancer cells that generate α particles and lithium ions. This process enables selective tumor cell destruction at the cellular level. Clinical evidence demonstrates significant therapeutic efficacy of BNCT in treatment-refractory malignancies including glioblastoma, recurrent head and neck carcinomas, and cutaneous melanoma. Compared to conventional radiotherapy, BNCT leverages its inherent biological selectivity to achieve precise eradication of geometrically complex tumors and microscopic metastases, demonstrating significant clinical potential. However, the widespread adoption of BNCT remains constrained by several limitations, most notably the inadequate tumor selectivity of boron delivery agents. This review examines the literature published since the emergence of BNCT clinical research in 1970 up to the present, summarizing key clinical practices and strategies to enhance therapeutic efficacy, including boron carriers, administration regimens, treatment planning systems, real-time boron monitoring, and combination therapies. It aims to provide guidance for the clinical application of BNCT and support its broader adoption in practice.
- 11 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17  (1)
Open AccessCore clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy
Boron Neutron Capture Therapy (BNCT) is a binary targeted radiotherapy modality based on nuclear capture reactions. This technique exploits the tumor-targeting capability of boron compounds and their high thermal neutron capture cross-section, inducing localized nuclear reactions within cancer cells that generate α particles and lithium ions. This process enables selective tumor cell destruction at the cellular level. Clinical evidence demonstrates significant therapeutic efficacy of BNCT in treatment-refractory malignancies including glioblastoma, recurrent head and neck carcinomas, and cutaneous melanoma. Compared to conventional radiotherapy, BNCT leverages its inherent biological selectivity to achieve precise eradication of geometrically complex tumors and microscopic metastases, demonstrating significant clinical potential. However, the widespread adoption of BNCT remains constrained by several limitations, most notably the inadequate tumor selectivity of boron delivery agents. This review examines the literature published since the emergence of BNCT clinical research in 1970 up to the present, summarizing key clinical practices and strategies to enhance therapeutic efficacy, including boron carriers, administration regimens, treatment planning systems, real-time boron monitoring, and combination therapies. It aims to provide guidance for the clinical application of BNCT and support its broader adoption in practice.
- Open Access
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1747607
Combined carbon ion radiotherapy and immunotherapy: leveraging the immunological advantages of carbon ion
Immunotherapy represents a systemic approach to cancer treatment; however, its effectiveness can be limited by intrinsic tumor resistance or immunosuppressive mechanisms within the tumor microenvironment. In contrast, carbon ion radiotherapy (CIRT) demonstrates considerable immunomodulatory potential owing to its distinct biological properties. The exposure of tumor-associated antigens, increased immune cell infiltration and activity, and modifications in the immune microenvironment after CIRT provide a mechanistic rationale for combining CIRT with immunotherapy. Furthermore, strategies aimed at converting the tumor microenvironment from immunosuppressive to immunostimulatory, or those targeting immune checkpoints, are currently under active exploration. This review summarizes the latest advances in combining heavy ion radiotherapy with immunotherapy, encompassing both preclinical and clinical studies. Based on the immunological advantages of CIRT, it provides a comprehensive summary and in-depth exploration of the potential of this combined treatment modality for future clinical applications, along with a theoretical foundation to support it.
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1747607
Open AccessCombined carbon ion radiotherapy and immunotherapy: leveraging the immunological advantages of carbon ion
Immunotherapy represents a systemic approach to cancer treatment; however, its effectiveness can be limited by intrinsic tumor resistance or immunosuppressive mechanisms within the tumor microenvironment. In contrast, carbon ion radiotherapy (CIRT) demonstrates considerable immunomodulatory potential owing to its distinct biological properties. The exposure of tumor-associated antigens, increased immune cell infiltration and activity, and modifications in the immune microenvironment after CIRT provide a mechanistic rationale for combining CIRT with immunotherapy. Furthermore, strategies aimed at converting the tumor microenvironment from immunosuppressive to immunostimulatory, or those targeting immune checkpoints, are currently under active exploration. This review summarizes the latest advances in combining heavy ion radiotherapy with immunotherapy, encompassing both preclinical and clinical studies. Based on the immunological advantages of CIRT, it provides a comprehensive summary and in-depth exploration of the potential of this combined treatment modality for future clinical applications, along with a theoretical foundation to support it.
- Open Access
- 9 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 29212
Pharmacokinetic, biodistribution, safety and efficacy studies of borophenylalanine (BPA) in BNCT in hepatocellular carcinoma cells and tumor-bearing mouse model
Boron neutron capture therapy (BNCT), using boronophenylalanine (BPA) as the main boron carrier, is a dual-targeted particle radiotherapy at the cellular level. Although BPA shows clinical promise in liver cancer, there is relatively little basic research on its effect on hepatocellular carcinoma. Therefore, we systematically evaluated the uptake, safety, pharmacokinetics, and therapeutic efficacy of BPA. Boron uptake in hepatocellular carcinoma cells (Hepa1-6, HepG2) was quantified by ICP-AES, revealing concentration- and time-dependent accumulation (plateau at 6 h), while CCK-8 assays indicated significant cytotoxicity at 24 h. Pharmacokinetic studies in Sprague-Dawley (SD) rats showed rapid boron distribution (peak at 25 ± 5.8 min) with a blood clearance half-life of 74.71 ± 52.22 min. In tumor-bearing mouse models, BPA achieved tumor-specific targeting, with tumor-to-normal tissue (T/N) and tumor-to-blood (T/B) ratios exceeding 2 and 4, respectively, at 2 h post-injection, followed by rapid systemic clearance. Cell viability significantly decreased after BPA-BNCT irradiation, and the tumor growth inhibition rate in mice reached 77%. BPA did not produce tissue damage in vivo, and there were no abnormalities in blood counts or liver or kidney function in vivo after irradiation. These findings suggest that BPA can be selectively enriched in hepatocellular tumors with good pharmacokinetics and therapeutic efficacy, supporting its clinical application in BNCT of hepatocellular carcinoma.
- 9 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 29212
Open AccessPharmacokinetic, biodistribution, safety and efficacy studies of borophenylalanine (BPA) in BNCT in hepatocellular carcinoma cells and tumor-bearing mouse model
Boron neutron capture therapy (BNCT), using boronophenylalanine (BPA) as the main boron carrier, is a dual-targeted particle radiotherapy at the cellular level. Although BPA shows clinical promise in liver cancer, there is relatively little basic research on its effect on hepatocellular carcinoma. Therefore, we systematically evaluated the uptake, safety, pharmacokinetics, and therapeutic efficacy of BPA. Boron uptake in hepatocellular carcinoma cells (Hepa1-6, HepG2) was quantified by ICP-AES, revealing concentration- and time-dependent accumulation (plateau at 6 h), while CCK-8 assays indicated significant cytotoxicity at 24 h. Pharmacokinetic studies in Sprague-Dawley (SD) rats showed rapid boron distribution (peak at 25 ± 5.8 min) with a blood clearance half-life of 74.71 ± 52.22 min. In tumor-bearing mouse models, BPA achieved tumor-specific targeting, with tumor-to-normal tissue (T/N) and tumor-to-blood (T/B) ratios exceeding 2 and 4, respectively, at 2 h post-injection, followed by rapid systemic clearance. Cell viability significantly decreased after BPA-BNCT irradiation, and the tumor growth inhibition rate in mice reached 77%. BPA did not produce tissue damage in vivo, and there were no abnormalities in blood counts or liver or kidney function in vivo after irradiation. These findings suggest that BPA can be selectively enriched in hepatocellular tumors with good pharmacokinetics and therapeutic efficacy, supporting its clinical application in BNCT of hepatocellular carcinoma.
- Open Access
- 27 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47  (10) , 4372-4373
Pathological complete response to neoadjuvant treatment in a patient with oral cancer using immunotherapy combined with chemotherapy
- 27 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47  (10) , 4372-4373
Open AccessPathological complete response to neoadjuvant treatment in a patient with oral cancer using immunotherapy combined with chemotherapy
- Open Access
- 1 December 2022
- Published by Springer Nature in BMC Medical Education
- Vol. 22  (1) , 1-8
Cancer screening and prevention education in standardized training residents: A cross-sectional survey in single center
Background: Standardized residency training is an essential aspect of enhancing the ability of cancer prevention and screening of residents. The current study was performed to investigate tumor prevention, screening literacy and the training demands of standardized training residents and explore related influencing factors. Methods: A cross-sectional survey was conducted among 320 residents of The First Hospital of Lanzhou University. An online, self-designed questionnaire was employed to investigate tumor prevention and screening, training status, and the requirements of residents. Data were analyzed using Fisher’s exact test. Results: The mean age of the 320 participants was 26.04 ± 1.85 years;133, 83, and 104 were in the 1st, 2nd and 3rd year of standardized training, respectively. Among the common carcinogenic factors, smoking, infectious agents, and drinking were more correlated with tumors by 72.19, 66.57, and 64.38% of the physicians, respectively. Excess body weight, an insufficient intake of fruits and dietary fiber, and a lack of exercise were correlated with tumors by only 26.56, 25, and 23.44% of the physicians, respectively. The proportion of physicians providing an accurate answer to the tumor screening question ranged from 23.13 to 93.13%. The lowest accuracy was 23.13% for the initial age of regular breast cancer screening in general-risk women. The maximum rate of the primary liver cancer screening methods was 93.13%. Postgraduates and residents of oncology practitioners considered excess body weight and the insufficient intake of fruits and dietary fiber more relevant to cancer (P < 0.05). Male residents viewed more associations between tumors and a lack of exercise and air pollution (P < 0.05). Overall, 71.26% of participants felt that their tumor prevention and screening knowledge was poor and 95.31% thought they needed standardized tumor prevention and screening training. Conclusion: Tumor prevention and screening literacy of standardized training residents should be further improved. There is a huge knowledge demand for tumor prevention and screening. Therefore, it is vital to build a training program in line with the requirements of cancer prevention and control efforts that focus on improving literacy among residents.
- 1 December 2022
- Published by Springer Nature in BMC Medical Education
- Vol. 22  (1) , 1-8
Open AccessCancer screening and prevention education in standardized training residents: A cross-sectional survey in single center
Background: Standardized residency training is an essential aspect of enhancing the ability of cancer prevention and screening of residents. The current study was performed to investigate tumor prevention, screening literacy and the training demands of standardized training residents and explore related influencing factors. Methods: A cross-sectional survey was conducted among 320 residents of The First Hospital of Lanzhou University. An online, self-designed questionnaire was employed to investigate tumor prevention and screening, training status, and the requirements of residents. Data were analyzed using Fisher’s exact test. Results: The mean age of the 320 participants was 26.04 ± 1.85 years;133, 83, and 104 were in the 1st, 2nd and 3rd year of standardized training, respectively. Among the common carcinogenic factors, smoking, infectious agents, and drinking were more correlated with tumors by 72.19, 66.57, and 64.38% of the physicians, respectively. Excess body weight, an insufficient intake of fruits and dietary fiber, and a lack of exercise were correlated with tumors by only 26.56, 25, and 23.44% of the physicians, respectively. The proportion of physicians providing an accurate answer to the tumor screening question ranged from 23.13 to 93.13%. The lowest accuracy was 23.13% for the initial age of regular breast cancer screening in general-risk women. The maximum rate of the primary liver cancer screening methods was 93.13%. Postgraduates and residents of oncology practitioners considered excess body weight and the insufficient intake of fruits and dietary fiber more relevant to cancer (P < 0.05). Male residents viewed more associations between tumors and a lack of exercise and air pollution (P < 0.05). Overall, 71.26% of participants felt that their tumor prevention and screening knowledge was poor and 95.31% thought they needed standardized tumor prevention and screening training. Conclusion: Tumor prevention and screening literacy of standardized training residents should be further improved. There is a huge knowledge demand for tumor prevention and screening. Therefore, it is vital to build a training program in line with the requirements of cancer prevention and control efforts that focus on improving literacy among residents.
- Open Access
- 4 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-16
Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification
Background. Glioma is a prevalent primary brain cancer with high invasiveness and typical local diffuse infiltration. Alternative splicing (AS), as a pervasive transcriptional regulatory mechanism, amplifies the coding capacity of the genome and promotes the progression of malignancies. This study was aimed at identifying AS events and novel biomarkers associated with survival for glioma. Methods. RNA splicing patterns were collected from The Cancer Genome Atlas SpliceSeq database, followed by calculating the percentage of splicing index. Expression profiles and related clinical information of glioma were integrated based on the UCSC Xena database. The AS events in glioma were further analyzed, and glioma prognosis-related splicing factors were identified with the use of bioinformatics analysis and laboratory techniques. Further immune infiltration analysis was performed. Results. Altogether, 9028 AS events were discovered. Upon univariate Cox analysis, 425 AS events were found to be related to the survival of patients with glioma, and 42 AS events were further screened to construct the final prognostic model ( ). Additionally, decreased expression of the splicing factors including Neuro-Oncological Ventral Antigen 1 (NOVA1), heterogeneous nuclear ribonucleoprotein C (HNRNPC), heterogeneous nuclear ribonucleoprotein L-like protein (HNRNPLL), and RNA-Binding Motif Protein 4 (RBM4) contributed to the poor survival in glioma. The immune infiltration analysis demonstrated that AS events were related to the proportion of immune cells infiltrating in glioma. Conclusions. It is of great value for comprehensive consideration of AS events, splicing networks, and related molecular subtype clusters in revealing the underlying mechanism and immune microenvironment remodeling for glioma, which provides clues for the further verification of related therapeutic targets.
- 4 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-16
Open AccessLandscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification
Background. Glioma is a prevalent primary brain cancer with high invasiveness and typical local diffuse infiltration. Alternative splicing (AS), as a pervasive transcriptional regulatory mechanism, amplifies the coding capacity of the genome and promotes the progression of malignancies. This study was aimed at identifying AS events and novel biomarkers associated with survival for glioma. Methods. RNA splicing patterns were collected from The Cancer Genome Atlas SpliceSeq database, followed by calculating the percentage of splicing index. Expression profiles and related clinical information of glioma were integrated based on the UCSC Xena database. The AS events in glioma were further analyzed, and glioma prognosis-related splicing factors were identified with the use of bioinformatics analysis and laboratory techniques. Further immune infiltration analysis was performed. Results. Altogether, 9028 AS events were discovered. Upon univariate Cox analysis, 425 AS events were found to be related to the survival of patients with glioma, and 42 AS events were further screened to construct the final prognostic model ( ). Additionally, decreased expression of the splicing factors including Neuro-Oncological Ventral Antigen 1 (NOVA1), heterogeneous nuclear ribonucleoprotein C (HNRNPC), heterogeneous nuclear ribonucleoprotein L-like protein (HNRNPLL), and RNA-Binding Motif Protein 4 (RBM4) contributed to the poor survival in glioma. The immune infiltration analysis demonstrated that AS events were related to the proportion of immune cells infiltrating in glioma. Conclusions. It is of great value for comprehensive consideration of AS events, splicing networks, and related molecular subtype clusters in revealing the underlying mechanism and immune microenvironment remodeling for glioma, which provides clues for the further verification of related therapeutic targets.
- Open Access
- 1 November 2021
- Published by Elsevier in Cancer Letters
- Vol. 521, 178-195
Carbon ion (12C6+) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway
- 1 November 2021
- Published by Elsevier in Cancer Letters
- Vol. 521, 178-195
Open AccessCarbon ion (12C6+) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway
- 1 July 2021
- Published by Elsevier in Lung Cancer
- Vol. 157, 116-123
Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases
- 1 July 2021
- Published by Elsevier in Lung Cancer
- Vol. 157, 116-123
Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases
- Open Access
- 19 February 2021
- Published by Springer Nature in Radiation Oncology
- Vol. 16  (1) , 1-6
Clinical features, treatment and outcomes in patients with tracheal adenoid cystic carcinoma: a systematic literature review
Background: Primary tracheal adenoid cystic carcinoma (TACC) is rare and originates from the minor salivary gland. Biologically, TACC results in delayed presentation, and the therapeutic effects of multimodal treatment differ across individuals. This study aimed to review cases of TACC to identify clinical features, imaging modalities, treatment, and patient outcomes across follow-ups.Methods: The PubMed, Web of Science and MEDLINE databases were searched to identify articles reporting cases of TACC. The study variables included in the analysis were patient demographics, biological characteristics, presenting symptoms, imaging modalities, treatments, follow-up times and survival outcomes.Results: A total of 76 articles and 1252 cases were included in this review. The most common presenting symptom was dyspnoea (86.0%), followed by cough (58.0%). Surgery alone (40.9%), surgery with postoperative radiotherapy (36.4%) and radiotherapy alone (19.2%) were used most frequently treatments modalities. Of the 1129 cases with disease control and survival data, there was no evidence of disease in 78.7%, local recurrence was reported in 3.8%. Distant metastasis rate was 24.9% of 418 reported cases, lung (44.2%) was the most commonly involved organ. The 5, 10 years survival rate of patients treated with surgery alone and surgery with postoperative radiotherapy were 86.4%, 55.6% and 97.3%, 44.4%, respectively.Conclusion: TACC most common presenting symptoms were dyspnoea, cough and shortness of breath. Surgery alone and surgery with postoperative radiotherapy are predominant treatment modalities. Both seems to provide a good result in term of disease control and long-term survival rate in patients with TACC.
- 19 February 2021
- Published by Springer Nature in Radiation Oncology
- Vol. 16  (1) , 1-6
Open AccessClinical features, treatment and outcomes in patients with tracheal adenoid cystic carcinoma: a systematic literature review
Background: Primary tracheal adenoid cystic carcinoma (TACC) is rare and originates from the minor salivary gland. Biologically, TACC results in delayed presentation, and the therapeutic effects of multimodal treatment differ across individuals. This study aimed to review cases of TACC to identify clinical features, imaging modalities, treatment, and patient outcomes across follow-ups.Methods: The PubMed, Web of Science and MEDLINE databases were searched to identify articles reporting cases of TACC. The study variables included in the analysis were patient demographics, biological characteristics, presenting symptoms, imaging modalities, treatments, follow-up times and survival outcomes.Results: A total of 76 articles and 1252 cases were included in this review. The most common presenting symptom was dyspnoea (86.0%), followed by cough (58.0%). Surgery alone (40.9%), surgery with postoperative radiotherapy (36.4%) and radiotherapy alone (19.2%) were used most frequently treatments modalities. Of the 1129 cases with disease control and survival data, there was no evidence of disease in 78.7%, local recurrence was reported in 3.8%. Distant metastasis rate was 24.9% of 418 reported cases, lung (44.2%) was the most commonly involved organ. The 5, 10 years survival rate of patients treated with surgery alone and surgery with postoperative radiotherapy were 86.4%, 55.6% and 97.3%, 44.4%, respectively.Conclusion: TACC most common presenting symptoms were dyspnoea, cough and shortness of breath. Surgery alone and surgery with postoperative radiotherapy are predominant treatment modalities. Both seems to provide a good result in term of disease control and long-term survival rate in patients with TACC.
- Open Access
- 1 February 2021
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 10  (2) , 938-952
Construction of a novel ceRNA network and identification of lncRNA ADAMTS9-AS2 and PVT1 as hub regulators of miRNA and coding gene expression in gastric cancer
Background: Studies on the interactions of single long non-coding RNA, microRNA, and mRNA have many limitations; therefore, it is necessary to study the complex regulatory network of gastric cancer (GC) pathogenesis systematically. Methods: In this study, gene and miRNA expression data for GC were downloaded from The Cancer Genome Atlas and used for transcriptome profiling, differential gene analysis, and construction of an lncRNA-miRNA-mRNA regulatory network in conjunction with an online database to identify the key genes and subnetworks in GC pathogenesis. Real-time quantitative polymerase chain reaction was used to detect the expression of hub lncRNAs in 54 paired GC and matched normal mucosal tissues. Results: We constructed an lncRNA-miRNA-mRNA competitive endogenous RNA regulatory network containing 1,626 network nodes and 2,704 interactions. LncRNA ADAMTS9-AS2 and PVT1 were identified as key node genes in this competitive endogenous RNA network. Quantitative reverse transcription-polymerase chain reaction revealed ADAMTS9-AS2 downregulation and PVT1 upregulation in 54 pairs of GC and normal tissues adjacent to the cancer tissues. Conclusions: This study systematically analysed the lncRNA-miRNA-mRNA regulatory network in GC and identified ADAMTS9-AS2 and PVT1 as key regulatory genes in this network, providing new understanding of GC pathogenesis and insights for its early diagnosis and treatment.
- 1 February 2021
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 10  (2) , 938-952
Open AccessConstruction of a novel ceRNA network and identification of lncRNA ADAMTS9-AS2 and PVT1 as hub regulators of miRNA and coding gene expression in gastric cancer
Background: Studies on the interactions of single long non-coding RNA, microRNA, and mRNA have many limitations; therefore, it is necessary to study the complex regulatory network of gastric cancer (GC) pathogenesis systematically. Methods: In this study, gene and miRNA expression data for GC were downloaded from The Cancer Genome Atlas and used for transcriptome profiling, differential gene analysis, and construction of an lncRNA-miRNA-mRNA regulatory network in conjunction with an online database to identify the key genes and subnetworks in GC pathogenesis. Real-time quantitative polymerase chain reaction was used to detect the expression of hub lncRNAs in 54 paired GC and matched normal mucosal tissues. Results: We constructed an lncRNA-miRNA-mRNA competitive endogenous RNA regulatory network containing 1,626 network nodes and 2,704 interactions. LncRNA ADAMTS9-AS2 and PVT1 were identified as key node genes in this competitive endogenous RNA network. Quantitative reverse transcription-polymerase chain reaction revealed ADAMTS9-AS2 downregulation and PVT1 upregulation in 54 pairs of GC and normal tissues adjacent to the cancer tissues. Conclusions: This study systematically analysed the lncRNA-miRNA-mRNA regulatory network in GC and identified ADAMTS9-AS2 and PVT1 as key regulatory genes in this network, providing new understanding of GC pathogenesis and insights for its early diagnosis and treatment.